Capital Investment Counsel LLC Sells 229 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Capital Investment Counsel LLC cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.4% during the fourth quarter, Holdings Channel.com reports. The fund owned 55,842 shares of the biopharmaceutical company’s stock after selling 229 shares during the period. Capital Investment Counsel LLC’s holdings in Gilead Sciences were worth $5,158,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. SteelPeak Wealth LLC bought a new position in shares of Gilead Sciences during the fourth quarter worth $4,921,000. Mayflower Financial Advisors LLC bought a new position in shares of Gilead Sciences during the 4th quarter valued at about $317,000. BSW Wealth Partners grew its position in shares of Gilead Sciences by 5.9% during the fourth quarter. BSW Wealth Partners now owns 6,048 shares of the biopharmaceutical company’s stock valued at $559,000 after purchasing an additional 335 shares in the last quarter. IRON Financial LLC increased its holdings in shares of Gilead Sciences by 2.7% in the fourth quarter. IRON Financial LLC now owns 10,169 shares of the biopharmaceutical company’s stock worth $939,000 after purchasing an additional 268 shares during the last quarter. Finally, Berkshire Bank lifted its position in shares of Gilead Sciences by 3.4% in the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock worth $314,000 after buying an additional 111 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares in the company, valued at $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the sale, the director now directly owns 8,920 shares in the company, valued at $815,198.80. This trade represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 456,234 shares of company stock worth $42,130,461. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on GILD. Mizuho raised their price target on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. BMO Capital Markets raised their target price on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $84.00 price target on shares of Gilead Sciences in a research note on Wednesday, December 11th. Maxim Group lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Finally, Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $97.96.

Gilead Sciences Price Performance

Shares of GILD stock opened at $93.85 on Wednesday. The company has a market capitalization of $116.96 billion, a P/E ratio of 1,042.78, a P/E/G ratio of 1.31 and a beta of 0.18. The company’s 50-day simple moving average is $91.88 and its two-hundred day simple moving average is $85.27. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.90. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.29 earnings per share. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.